A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People.

Trial Profile

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
  • Indications Cardiovascular disorders; Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Novartis
  • Most Recent Events

    • 19 Jul 2013 Status changed from active, no longer recruiting to discontinued.
    • 17 Jun 2013 Results presented at the 23rd European Meeting on Hypertension.
    • 27 Oct 2012 Planned number of patients changed from 1758 to 11000 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top